Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes adverse events compared with no treatment (very low certainty).
1 finding from 1 review
RR 5 [0.25, 101.81]
110 participants
Very low
Adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher withdrawal due to adverse events compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Adverse effect/event: 2. Adverse effects ‐ any ‐ medium‐termonly · participants with acne
It is very uncertain whether benzoyl peroxide changes total number of participants with any adverse events (medium‐term… compared with salicylic acid (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found